WO2006043614A1 - Procédé d’immunoanalyse de membrane - Google Patents

Procédé d’immunoanalyse de membrane Download PDF

Info

Publication number
WO2006043614A1
WO2006043614A1 PCT/JP2005/019271 JP2005019271W WO2006043614A1 WO 2006043614 A1 WO2006043614 A1 WO 2006043614A1 JP 2005019271 W JP2005019271 W JP 2005019271W WO 2006043614 A1 WO2006043614 A1 WO 2006043614A1
Authority
WO
WIPO (PCT)
Prior art keywords
membrane
enzyme
sample
antibody
antigen
Prior art date
Application number
PCT/JP2005/019271
Other languages
English (en)
Japanese (ja)
Inventor
Shosaku Motoda
Takashi Miyazawa
Original Assignee
Denka Seiken Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denka Seiken Co., Ltd. filed Critical Denka Seiken Co., Ltd.
Publication of WO2006043614A1 publication Critical patent/WO2006043614A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0681—Filter

Definitions

  • the present invention relates to a simple flow-through membrane enzyme immunoassay method for detecting an object to be detected in a specimen sample and a kit used in this method.
  • a membrane assembly method in particular, an assembly method using a membrane such as -trocellulose or a membrane such as a filter is generally known, and a flow-through method and a lateral flow method are used.
  • a flow-through method and a lateral flow method are used.
  • the former allows the solution containing the object to be detected to pass in a direction perpendicular to the membrane, and the latter allows the solution to be developed in the horizontal direction.
  • a label is detected by forming a complex of a capture substance that specifically binds to the detection target, a detection target, and a labeling substance that specifically binds to the detection target on the membrane.
  • Quantification means that the detection of an object to be detected is common in terms of quantification.
  • the patient force is determined to be positive even though the sample to be detected is not present in the sample, based on the analysis of the sample actually collected.
  • false positives may occur. If a false positive reaction occurs when testing for a pathogen infection, it will give false information about the disease, so it will not only delay the identification of the cause, but will take inappropriate measures and make the condition more serious. It can have serious consequences. Therefore, suppressing false positives is a very important issue from the main purpose of simple test methods.
  • a specimen is highly diluted, or a buffer containing a surfactant, a basic amino acid, an inorganic salt, or the like is used as a solution for diluting the specimen (see Patent Document 1).
  • a buffer solution containing a surfactant, a basic amino acid, an inorganic salt, or the like is used as a cleaning solution (see Patent Document 1), and a filter is passed when adding a sample (see Patent Document 2). Ingenuity has been made!
  • the flow-through type membrane enzyme immunoassay method using an enzyme for labeling is an excellent method for high-sensitivity measurement.
  • the sample is diluted or a washing solution is used. This is a problem as a simple assembly method with many detection operation steps.
  • a specimen sample is prepared by suspending a specimen collected from a patient in a buffer solution, filtered using a filtration filter, and dropped onto an accessory device.
  • Judgment is made based on the presence or absence of coloration on the membrane.
  • the conventional method requires many steps to detect the detection target.
  • Patent Document 1 Japanese Patent Laid-Open No. 2003-279577
  • Patent Document 2 JP 2004-28875 A
  • an object of the present invention is to reduce an operation process for detecting an object to be detected contained in a sample sample in the flow-through type membrane zymno assay method.
  • a further object of the present invention is to provide a method for accurately and rapidly detecting an object in a specimen sample, and a kit therefor. Specifically, it is an object to provide a method and a kit that do not require the washing step of the present invention.
  • the inventor of the present application reduces the nonspecific reaction by filtering a specimen sample using a filtration filter device, and adds a surfactant and Z or urine serum albumin to the specimen diluent.
  • a sample sample containing a target substance is filtered on an assembly device equipped with a membrane to which an antigen is bound using a filtration filter device, and then dropped, and the target substance is captured by the capture antibody or antigen on the membrane to be detected.
  • An enzyme-labeled reagent in which a substance that binds to the target substance is labeled with an enzyme is dropped on the membrane on which the target substance has been trapped, and the capture antibody or antigen target substance. It was found that the washing step can be omitted in the flow-through type membrane enzyme immunoassay method, which is an operation step of forming a complex and subsequently dropping the substrate for the enzyme.
  • the present invention has been completed.
  • a sample sample diluted with a buffer solution was filtered on a membrane of an assembly device equipped with a membrane to which a capture antibody or a capture antigen was bound to capture an object to be detected, using a filtration filter device. It is dropped later to capture the target to be captured by the capture antibody or capture antigen, and an enzyme labeling reagent that binds to the target is dropped on the membrane on which the target is captured, and the capture antibody or capture antigen is detected.
  • a flow-through type membrane enzyme that does not include a step of forming an immunocomplex of a labeling reagent and subsequently dripping a substrate solution for the enzyme onto the membrane and washing with a washing solution.
  • a group force consisting of a pharyngeal or nasal wipe, pharyngeal or nasal wash and nasal aspirate is also selected [1]-[8]
  • a flow-through membrane zymno assay kit for detecting the presence of an analyte in a sample without using a wash solution including:
  • a membrane attached with a capture antibody or antigen for capturing an object to be detected comprising a membrane having a pore diameter of 3 to 12 m,
  • the invention's effect [0021] With the method and kit of the present invention, it was possible to reduce the number of detection operation steps, and to establish an easy-to-use and highly reliable assembly method.
  • FIG. 1 is a plan view of a flow-through type membrane zymno assay device according to an embodiment of the present invention.
  • FIG. 2 is a cross-sectional view taken along the line I ⁇ in FIG.
  • FIG. 3 is a view showing an embodiment of a specimen sample filtration tube used in the present invention.
  • FIG. 4 is a perspective view of the distal end portion of the specimen sample filtration tube of FIG. 3.
  • the method of the present invention is a simple assembly method for an object to be detected in an analyte sample using an assembly device equipped with a capture antibody or an antigen-bound membrane for capturing the analyte. After being filtered using a filtration filter, the solution is dropped on the membrane to capture the target to be captured by the capture antibody or antigen on the membrane, and the enzyme reacts with the target on the membrane where the target is captured. Drop the labeling reagent and capture antibody or Is a flow-through membrane enzyme that forms an immune complex of an antigen to be detected and an enzyme labeling reagent, and then drops the substrate for the enzyme onto the membrane on which the immune complex has been formed. This is characterized in that the cleaning process is omitted in accordance with the Immunoassay method.
  • a specimen sample is prepared by diluting a specimen collected from a patient with a buffer solution, filtered using a filtration filter, and dropped on an accessory device.
  • reaction stop solution When determining the presence or absence of color development, a reaction stop solution may be used as necessary.
  • An assembly device equipped with a membrane is a device comprising a membrane on which a capture antibody that specifically binds to an object to be detected is immobilized. It is.
  • Such an accessory device is preferably an accessory device that uses a flow-through membrane enzyme control method.
  • the flow-through type membrane zymno assay device is, for example, a device as shown in Figs.
  • FIG. 1 is a plan view of the apparatus
  • FIG. 2 is a cross-sectional view taken along the line I ⁇ of FIG.
  • a is an adapter having an opening for dropping the prepared specimen sample and having holes (A hole and B hole) through which the sample passes on the bottom surface.
  • b is a membrane to which a capture antibody that specifically binds to an object to be detected is bound
  • c is a member that absorbs liquid.
  • the material of the membrane in the membrane assembly device includes non-woven fabric, paper, nitrocellulose, glass fiber, silica fiber, cellulose ester, nylon 6, 6 and a group force composed of a mixture of cellulose ester and -trocellulose.
  • the ones that are selected are listed and are particularly preferred
  • An example is a microporous material made of trocellulose.
  • a mixture of the cellulose ester and -trocellulose can also be suitably used.
  • the membrane has a pore size or retained particle size that is not less than the pore size of the filtration filter or the retained particle size, and is preferably 3 to 12 ⁇ m, particularly preferably 3 to 5 ⁇ m.
  • the thickness of the membrane is not particularly limited, but is usually about 100 to 200 / ⁇ ⁇ .
  • an antibody or an antigen that captures the detection target by binding specifically to the detection target by an antigen-antibody reaction to form an antigen-antibody complex is solid-phased.
  • the capture antibody to be used differs depending on the substance to be detected.
  • the object to be detected is bacteria, viruses, hormones, other clinical markers, etc.
  • the antigen include a purified natural antigen or a recombinant antigen.
  • the method for binding such a capture antibody to the above-described membrane may be physical adsorption or chemical binding.
  • the membrane to which the capture antibody is bound is prepared, for example, by applying a solution obtained by diluting the capture antibody with a buffer or the like to the membrane and then drying it.
  • the membrane assembly device of the present invention may include a liquid absorbing member that absorbs the liquid that has passed through the membrane.
  • the sample collected from the patient is diluted with a buffer solution to obtain a sample sample, which is filtered using a filtration filter.
  • the pore size (diameter) or retained particle size of the filtration filter is 0.1-0.
  • the pore size or retained particle size of the filtration filter is extremely important in omitting the above-described washing step. If the pore size or retained particle size is too large, non-specific binding may occur on the membrane, indicating false positives. On the other hand, if it is too small, the filter itself will be clogged due to viscous substances and agglomerates present in the sample, and there is a force that makes filtration impossible! It is inappropriate because of its purpose of use in simple inspection methods.
  • the material of the filtration filter is not particularly limited, but is preferably glass fiber or -trosse It is roulose.
  • the filtration filter 1 may be provided in an opening for dropping the specimen of the assembly device.
  • the filtration filter is used by being attached to a specimen sample filtration device.
  • the specimen sample filtration device is a container-like device having a single filtration filter, for example, a tubular device (a specimen sample filtration tube).
  • a method in which a filtration filter is attached to the tip of a filtration tube, a sample diluted with a buffer solution is poured into the filtration tube, filtered through a filtration filter attached to the tip, and the filtrate is dropped onto a membrane in an accessory device Is convenient and preferable.
  • FIGS. A schematic view of one embodiment of this filtration tube is shown in FIGS.
  • the filtration tube has a shape composed of a tip part d and a body part e, and a filtration filter f is provided inside the tip part as shown in FIG.
  • the specimen sample is filtered through the filtration filter f, and the filtrate is dropped on the membrane of the accessories.
  • the main body e is made of a flexible material such as polyethylene or polyethylene terephthalate (PET), the sample can be filtered easily by applying pressure to the inside with the filter attached. ,preferable.
  • PET polyethylene or polyethylene terephthalate
  • the object to be detected in the present specification is not limited in any way, and may be any antigenic substance capable of producing an antibody corresponding thereto.
  • virus antigens such as influenza virus, adenovirus, RS virus, HAV, HBs, HCV, HIV, EBV, Norwalk-like virus, Chlamydia 'Tracomatis, Streptococcus, Bordetella pertussis, Helicopactor' H.
  • the detected object may be an antibody, for example, influenza virus.
  • Virus adenovirus
  • RS virus HAV
  • HBs HCV
  • HIV EBV
  • Norwalk virus etc.
  • bacterial antigens such as Gondi, Borrelia, Legionella, Bacillus anthracis, MRSA, toxins produced by bacteria, and mycoplasma lipid antigens.
  • the specimen may be, for example, a pharynx or nasal cavity wipe collected from a patient's pharynx or nasal cavity, a sterile swab, a pharyngeal or nasal rinse, a nasal aspirate, saliva, serum, stool suspension Liquid, urine, culture solution, etc. can be used, but the specimen obtained in this way is diluted in a buffer solution and subjected to assay.
  • a buffer solution used for dilution of the specimen a buffer solution or the like usually used in antigen detection or quantification by an immunological technique such as Enzyme Immunoassay or immunoagglutination can be used. More specifically, the force includes Tris buffer solution, Good buffer solution and the like, but is not limited thereto.
  • the pharynx collected using a specimen collection device such as a sterilized cotton swab! /, If the specimen has viscosity such as nasal wipes, liquid, pharynx or nasal rinse, etc.
  • the sample floats in the buffer that dilutes.
  • the buffer is referred to as a sample suspension buffer.
  • the buffer for diluting the specimen contains animal-derived serum albumin such as surfactant 0.2 to 10 (w / v)%, ushi serum albumin (BSA) at the final concentration when the specimen is added. 1 to 5 (w / v)%, or an appropriate concentration of inorganic salt, etc. can be contained, and by diluting with these buffers, components other than the detection target contained in the sample.
  • animal-derived serum albumin such as surfactant 0.2 to 10 (w / v)%, ushi serum albumin (BSA) at the final concentration when the specimen is added. 1 to 5 (w / v)%, or an appropriate concentration of inorganic salt, etc.
  • BSA ushi serum albumin
  • Triton X-100 (trade name): polyethylene glycol mono-p isooctyl phenol ether, Tween 20: polyoxyethylene sorbitan monolaurate, Tween 80: polyoxyethylene sorbitan monooleate,
  • Nonidet P—40 Nodette P—40
  • ZWITTERGENT 3—14 n—Tetradecyl N, N Dimethyl-3—Ammonia 1 Propanesulfonate
  • CHAPS 3 — [(3 colamidopropyl) dimethylammonium -O] Propanesulfonic acid, sodium dodecyl sulfate (SDS), etc., or a mixture of two or more of these can be used, but is not limited thereto.
  • the enzyme labeling reagent is an enzyme labeling reagent in which a substance that specifically binds to an object to be detected is labeled with an enzyme.
  • the substance that specifically binds to the detection target is not limited, but an antigen or antibody that specifically binds to the detection target is desirable.
  • the detected substance is a viral or bacterial antigen, it is an antibody against the viral antigen or bacterial antigen, which is labeled with an enzyme.
  • the detection target is an antibody, it is an antibody to which the antibody binds or an antibody against the antibody, which is labeled with an enzyme.
  • a polyclonal antibody, a monoclonal antibody, or the like that specifically reacts with and binds to an object to be detected is used.
  • Such an enzyme labeling reagent detects a complex by adding a substrate solution of the enzyme that generates a substance detectable by a colorimetric method or a fluorescence method by a reaction catalyzed by the enzyme. Can go out.
  • Examples of the enzyme used for enzyme labeling include alkaline phosphatase and peroxidase.
  • the substance can be labeled with an enzyme by a known method.
  • the substrate solution is a substrate for the enzyme used as a label for the enzyme labeling reagent, and generates a substance detectable by a colorimetric method or a fluorescence method by a reaction catalyzed by the enzyme.
  • Specific examples thereof include 5-bromo-4-chloro-tri-indolyl phosphate trotetrazolium blue and tetramethylbenzidine.
  • the substrate solution When the substrate solution is dropped on the membrane, most of the substrate solution passes through the membrane within a short time and is absorbed by the liquid absorbing member, and the substrate solution remaining on the membrane undergoes a color reaction by the labeling enzyme. . Therefore, since the substrate solution that passes through the membrane exhibits a cleaning action, a surfactant generally used in Enzymno Assay is added to the substrate solution to further perform the cleaning action. To reduce non-specific binding.
  • the concentration of the surfactant is preferably 0.02 to: L (w / v)%.
  • the present invention also includes an accessory kit for performing the above method.
  • the accessory kit of the present invention preferably includes at least the following 1 to 5, each having the above-mentioned characteristics.
  • the filtration filter is preferably attached to a specimen sample filtering device such as the specimen sample filtration tube described above.
  • a negative control that also has a buffer solution for testing the activity of the kit
  • a positive control such as a buffer solution containing a detection target, and a reaction stop solution
  • it may include a sample collection device such as a sterile swab used to collect pharyngeal or nasal wipes.
  • BALBZc mice were immunized with influenza A virus antigens, spleens were removed from mice reared for a certain period of time, and mice were obtained by the method of Keller et al., Nature, vol, 256, p495-497 (19 75)). Fused with myeloma cells (P3 X 63). The obtained fused cells (hybrid cells) are maintained in a 37 ° C incubator, and the antibody activity of the supernatant is confirmed by ELISA using a plate with a solid phase of influenza A virus NP antigen. ⁇ ⁇ (monocloning) was performed. The obtained two cell lines were each intraperitoneally administered to pristane-treated BALB Zc mice, and about 2 weeks later, antibody-containing ascites was collected.
  • IgG was purified from the obtained ascites by a affinity chromatography method using a protein A column to obtain two types of purified anti-influenza A virus NP antibodies.
  • the treated solution was fractionated on an Ultrogel AcA34 column to obtain a purified fraction of anti-A-type influenza virus NP antibody F (ab ′) 2.
  • the fraction was concentrated to about 1 OmgZmL, mixed with 0.1M mercaptoethylamine at a volume ratio of 10: 1, and reduced at 37 ° C. for 90 minutes.
  • the treatment solution was fractionated with an Ultrogel AcA34 column to obtain an anti-influenza A influenza virus NP antibody Fab and purified fraction, and then concentrated to about 1 mL.
  • an enzyme-labeled anti-influenza B virus antibody was obtained in the same manner as (1).
  • a device having the same configuration as that shown in FIGS. 1 and 2 was used.
  • As the membrane a trocellulose membrane (size 2 ⁇ 3 cm, thickness 125 m) having a pore diameter of 3 m was used.
  • the solid phase of the capture antibody on the membrane was performed by spotting two antibody solutions onto the -trocellulose membrane.
  • purified anti-influenza A virus NP antibody that was not used for labeling was diluted with purified water so as to be contained in lmgZmL, and filtered through a 0.22 ⁇ m pore size filter.
  • influenza A virus and influenza B virus cultured in hatched chicken eggs were used.
  • Influenza virus buffer for specimen suspension (Triton X—100 l (w / v)%, urine serum albumin 4 (w / v)%, sodium chloride 0.15M, sodium azide 0.09
  • Tris buffer solution pH 8.0
  • each of the enzyme-labeled anti-type influenza virus antibody is dropped into the hallway and the enzyme-labeled anti-type B influenza virus antibody is dropped into the hall B, and the enzyme-labeled antibody is placed on the liquid absorbing member. Let stand until completely absorbed.
  • the adapter was removed, and the substrate solution (5 bromo-4 chloro-3 indolyl phosphate 0.15 mgZmL, nitrotetrazolium blue 0.3 mg / mL, sodium chloride 5 mM, Triton X-100 0.1% (w / v)%, sodium azide contained in 0.09 (w / v)% 0.1M A tris buffer solution, ⁇ 9.5), was added dropwise to each of A hole and B hole in an amount of 250 ⁇ L to initiate the color reaction.
  • the substrate solution 5 bromo-4 chloro-3 indolyl phosphate 0.15 mgZmL, nitrotetrazolium blue 0.3 mg / mL, sodium chloride 5 mM, Triton X-100 0.1% (w / v)%, sodium azide contained in 0.09 (w / v)% 0.1M
  • a tris buffer solution ⁇ 9.5
  • influenza A virus was used as a specimen, A-hole was positive up to an influenza A virus concentration of 10 5 (pfo / mL), B-holes were all negative, and it was confirmed that influenza A virus could be detected specifically. It was.
  • influenza B virus when influenza B virus was used as a specimen, B-hole was positive up to a B-type influenza virus concentration of 10 5 (pfo / mL), all A-holes were negative, and the influenza B virus was specifically detected. It was confirmed that it could be detected.
  • influenza virus can be specifically detected with high sensitivity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Clinical Laboratory Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L’invention concerne un procédé d’analyse facile d’emploi et extrêmement fiable, grâce auquel on peut réduire le nombre de phases de procédure de détection lors d’un procédé de test d’un échantillon en utilisant un procédé d’immunoanalyse de membrane de type à écoulement traversant, et un kit à utiliser dans le cadre dudit procédé. A savoir l'invention concerne un procédé d’immunoanalyse de membrane de type à écoulement traversant simplifié permettant de détecter un sujet dans un échantillon de test en utilisant un appareil d’analyse pourvu d’une membrane à laquelle est fixé un anticorps ou un antigène d’adsorption destiné à la capture du sujet à détecter, caractérisé en ce qu’il consiste à filtrer l’échantillon de test en utilisant un filtre, puis à le laisser tomber, pour permettre à l’anticorps ou à l’antigène d’adsorption sur la membrane de capturer le sujet à détecter, à verser un réactif d’étiquetage par enzyme, comprenant une substance étiquetée par enzyme capable de réagir avec le sujet de détection, sur la membrane portant le sujet de détection une fois capturé, et à détecter la présence du sujet de détection dans l’échantillon de test sans recourir à une phase de lavage ; et un kit permettant de détecter la présence d’un sujet dans un échantillon de test.
PCT/JP2005/019271 2004-10-20 2005-10-20 Procédé d’immunoanalyse de membrane WO2006043614A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-305836 2004-10-20
JP2004305836A JP2006118936A (ja) 2004-10-20 2004-10-20 メンブランエンザイムイムノアッセイ法

Publications (1)

Publication Number Publication Date
WO2006043614A1 true WO2006043614A1 (fr) 2006-04-27

Family

ID=36203029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/019271 WO2006043614A1 (fr) 2004-10-20 2005-10-20 Procédé d’immunoanalyse de membrane

Country Status (2)

Country Link
JP (1) JP2006118936A (fr)
WO (1) WO2006043614A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113834929A (zh) * 2021-09-27 2021-12-24 山东康华生物医疗科技股份有限公司 一种用于过敏原检测的检测膜条、检测卡以及检测试剂盒

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774555A1 (fr) * 2009-09-25 2011-03-31 Glaxosmithkline Biologicals S.A. Test d'immunodiffusion pour virus de la grippe
JP5139395B2 (ja) * 2009-10-19 2013-02-06 株式会社共立理化学研究所 鉛イオンの簡易分析器及びそれを用いた鉛イオンの分析方法
JP5139396B2 (ja) * 2009-10-19 2013-02-06 株式会社共立理化学研究所 水銀イオンの簡易分析器及びそれを用いた水銀イオンの分析方法
CN110785649A (zh) 2017-06-26 2020-02-11 埃斯特万·门多萨 样本过滤装置
JP2022018768A (ja) * 2020-07-16 2022-01-27 デンカ株式会社 簡易鼻腔粘膜表面付着粘液の採取方法および該検体中の被検出物を検出するための検査キット

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05126832A (ja) * 1991-10-31 1993-05-21 Fujirebio Inc 免疫分析装置及び免疫分析方法
JPH05172819A (ja) * 1991-06-07 1993-07-13 Eastman Kodak Co 乾式イムノアッセイ分析要素及びそれを用いたイムノアッセイ
JP2004248531A (ja) * 2003-02-18 2004-09-09 Tokushima Ken きのこエキス及びその製造方法
JP2004279208A (ja) * 2003-03-14 2004-10-07 Denka Seiken Co Ltd フロースルー型リガンド検出装置及びその製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05172819A (ja) * 1991-06-07 1993-07-13 Eastman Kodak Co 乾式イムノアッセイ分析要素及びそれを用いたイムノアッセイ
JPH05126832A (ja) * 1991-10-31 1993-05-21 Fujirebio Inc 免疫分析装置及び免疫分析方法
JP2004248531A (ja) * 2003-02-18 2004-09-09 Tokushima Ken きのこエキス及びその製造方法
JP2004279208A (ja) * 2003-03-14 2004-10-07 Denka Seiken Co Ltd フロースルー型リガンド検出装置及びその製造方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113834929A (zh) * 2021-09-27 2021-12-24 山东康华生物医疗科技股份有限公司 一种用于过敏原检测的检测膜条、检测卡以及检测试剂盒

Also Published As

Publication number Publication date
JP2006118936A (ja) 2006-05-11

Similar Documents

Publication Publication Date Title
US8404479B2 (en) Simple membrane assay method and kit
JP5340575B2 (ja) イムノクロマトグラフィー用試験具
JP4800739B2 (ja) アッセイ用媒体及びアッセイ方法
US20150079581A1 (en) Detection kit for influenza a virus
JP2008014751A (ja) 着色ラテックス粒子を用いるメンブレンアッセイ法およびキット
JP2013072663A (ja) マイコプラズマ・ニューモニエ検出用イムノクロマトグラフィー試験デバイスおよびキット
WO2006073153A1 (fr) Procédé d’analyse simplifié pour détecter de multiples sujets
JP4286157B2 (ja) メンブレンアッセイ法
WO2006043614A1 (fr) Procédé d’immunoanalyse de membrane
JP4976068B2 (ja) 簡易イムノアッセイ用検体浮遊液およびアッセイ方法
JP2014098715A (ja) 着色ラテックス粒子を用いるメンブレンアッセイ法およびキット
JP4115728B2 (ja) フロースルー式検査法用組成物、これを用いたキット及び検査法
JP3848599B2 (ja) 簡易メンブレンアッセイ法及びキット
JP5500791B2 (ja) 新規検査方法及びそれに用いる検査キット
JP2006084351A (ja) 検体浮遊液組成物、キット及び検査方法
WO2022024925A1 (fr) Réactif pour test présentant une amélioration du point de vue de l'abaissement de signaux
JP5911404B2 (ja) 簡易メンブレンアッセイ法及びキット
JP6405339B2 (ja) 簡易メンブレンアッセイ法及びキット
JP2009002961A (ja) 簡易メンブレンアッセイ法及びキット
JP4276898B2 (ja) メンブレンアッセイ法
JP2012083370A (ja) 着色ラテックス粒子を用いるメンブレンアッセイ法およびキット
JP2017036917A (ja) ヘリコバクター・ピロリの検出方法
JP6405269B2 (ja) 簡易メンブレンアッセイ法及びキット
JP2020046436A (ja) 簡易メンブレンアッセイ法及びキット
US20240011978A1 (en) Test kit with improved specificity by suppressing false positives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05795463

Country of ref document: EP

Kind code of ref document: A1